Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Immuno-Oncology: What To Watch At ASCO 2018

May 18 2018

• By Emily Hayes and Jessica Merrill

Neon Light Sign Lungs Icon

Related Content

Celgene's CAR-T Leadership Goals Advance At ASH 2017

Dec 12 2017

Merck's Keytruda Set For Expanded Use As Lung Cancer Monotherapy

Apr 10 2018

NewLink CEO Reflects On Golden Age And Rapid Fall Of IDO

May 15 2018

Other ASCO 2018 Highlights – It’s Not All IO

May 18 2018

Merck Files Keytruda/Chemo Combo Early With FDA In 1L Squamous Lung Cancer

May 03 2018

Celgene Seeks CAR-T Leadership, Hematology Diversification With Juno Buy

Jan 23 2018

Roche Gains With Tecentriq IMpower131 NSCLC Data, But For How Long?

Mar 20 2018

Nektar's NKTR-214 IO Deal With Bristol Looks Even Sweeter With More Data

Mar 03 2018

Roche's IMpower150 Gets AACR Applause But Merck's KEYNOTE-189 Big Winner

Apr 17 2018

In The Hot Seat: Bristol Defends IO Position Amid Sliding Stock And Forecasts

Apr 18 2018

Incyte/Merck's ECHO-301 Failure Casts More Shadow On IDO Space

Apr 06 2018

Merck's Keytruda Enjoys Clean Sweep In Lung Cancer, At Bristol's Expense

Apr 17 2018

Related Companies

Merck & Co., Inc.

Roche Holding AG

Bristol Myers Squibb Company

Regeneron Pharmaceuticals, Inc.

Incyte Corporation

Dynavax Technologies Corporation

Nektar Therapeutics

Jounce Therapeutics, Inc.

Bristol Myers Squibb Company

Genetix Biotherapeutics

Bristol Myers Squibb Company

Novartis AG

Gilead Sciences, Inc.

Additional Topics

ImmunoOncology Clinical Trials Research & Development Cancer BioPharmaceutical

More from Immuno-oncology

More from Anticancer

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window